• Risk assessment and frequency of cervical pathology in women taking combined oral contraceptives on the background of hpv infection
To content

Risk assessment and frequency of cervical pathology in women taking combined oral contraceptives on the background of hpv infection

HEALTH OF WOMAN.2015.5(101):62–65; doi 10.15574/HW.2015.101.62
 

Risk assessment and frequency of cervical pathology in women taking combined oral contraceptives on the background of hpv infection
 

Golyuk N. Y., Pyrohova V.

Lviv national medical University named Danylo Galitsky
 

Despite numerous studies, the problem of diagnosis and treatment of diseases associated with HPV in women taking combined oral contraceptives remains relevant because of the sharp increase in the incidence, in large contagious and high oncogenic potential of HPV. The article presents the results of the risk assessment and frequency of cervical pathology at HPV infection in users of oral contraceptives. Based on these studies found that consumers COC is considerable frequency of background cervical pathology, Chlamydia infection and infection with herpes simplex virus type II. Consumers COC has been a significant level of HPV infection (61.5%), while women without cervical pathology HPV infection was 28.3%, and patients with underlying diseases of the cervix, it increases to 66.2%, while the High risk HPV types detected in 47.8% of cases. In patients with CIN I/II simultaneously identified types of HPV prevalence High risk types (66.7%). The findings suggest the need for more careful study of women COC users, for the detection, treatment and prevention of precancerous lesions and cervical cancer.
 

Key words: hormonal contraception, the pathology of the cervix, HPV
 

REFERENCES

1. Волков ВГ. 2001. Гормональная контрацепция и рак шейки матки. Вестник новых медицинских технологий. Тематический выпуск «Проблемы клинической медицины в аспекте экологопрофессионального риска» VIII;3:96–98.

2. Воробйова ЛІ. 2010. Сучасні підходи до діагностики, лікування і профілактики раку шийки матки. Жіночий лікар 5(31):8–21.

3. Єгоров ОО. 2010. Комплексна діагностика передпухлинних захворювань шийки матки. Жіночий лікар 5(31):37–43.

4. Назарова НМ, Кондриков НИ. 2000. Трехфазная контрацепция и патология шейки матки. Вестник Российской ассоциации акушеров-гинекологов 3:122–124.

5. Прилепская ВН, Сотникова ЕИ. 1994. Контрацепция в планировании семьи. Акушерство и гинекология 4:60–62.

6. Ульрих ЕА, Кутушева ГФ, Урманчеева АФ. 2009. Онкологические аспекты контрацепции. Практическая онкология 10;4:254–264.

7. Hussain SK, Madeleine MM, Johnson LG et al. 2008. Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin-2. Cancer Epidemiol. Biomarkers. Prev. 17;7:1790–1799. http://dx.doi.org/10.1158/1055-9965.EPI-07-2753; PMid:18628433 PMCid:PMC2497438

8. Moreno V, Bosch F, Munoz N et al. 2002. Effect of oral contraceptives on risc of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 30:1085–1092. http://dx.doi.org/10.1016/S0140-6736(02)08150-3

9. Franceschi S. 2005. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results in Cancer Research 166:277–297. http://dx.doi.org/10.1007/3-540-26980-0_18; PMid:15648196

10. Shew ML, Weaver B, Tu W et al. 2013. High frequency of human papillomavirus detection in the vagina before first vaginal intercourse among females enrolled in a longitudinal cohort study. Jour. Infect. Dis. 207;6:1012–1015. http://dx.doi.org/10.1093/infdis/jis775; PMid:23242538 PMCid:PMC3571440

11. Bright PL, Norris TA, Morrison CS et al. 2011. Hormonal contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 84(5):512–519. http://dx.doi.org/10.1016/j.contraception.2011.02.002; PMid:22018127 PMCid:PMC4262923

12. Pike MC, Spicer DV. 2000. Hormonal contraception and chemoprevention of female cancers. EndocrineRelated Cancer. 7:73–83. http://dx.doi.org/10.1677/erc.0.0070073; PMid:10903525

13. Hariri S, Unger ER, Powell SE et al. 2012. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J. Infect. Dis. 206(12):1878–1886. http://dx.doi.org/10.1093/infdis/jis627; PMid:23045628

14. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16.573 women with cervical cancer and 35.509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007. 370(9599):1609–1621. http://dx.doi.org/10.1016/S0140-6736(07)61684-5

15. Albrow R, Blomberg K, Kitchener H et al. 2014. Interventions to improve cervical cancer screening uptake amongst young women: a systematic review. Acta Oncol. 53;4:445–451. http://dx.doi.org/10.3109/0284186X.2013.869618; PMid:24660768

16. La Vecchia C, Boccia S. 2014. Oral contraceptives, human papillomavirus and cervical cancer. Eur. Jour. Cancer Prev. 23;2:110–112. http://dx.doi.org/10.1097/CEJ.0000000000000000; PMid:24469243

17. Kreimer AR, Schiffman M, Herrero R et al. 2012. Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int. Jour. Cancer 13;1:211–218. http://dx.doi.org/10.1002/ijc.26349; PMid:21823117 PMCid:PMC3334438

18. Monsonego J. 2013. HPV testing in prevention of cervical cancer: practices and current trends. Ann. Biol. Clin. 71:27–32.

19. Moreno V, Bosch FX, Munoz N et al. 2002. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359(9312):1085–1092. http://dx.doi.org/10.1016/S0140-6736(02)08150-3

20. Murphy J, Mark H. 2012. Cervical cancer screening in the era of human papillomavirus testing and vaccination. Jour. Midwifery Womens Health 57;6:569–576. http://dx.doi.org/10.1111/j.1542-2011.2012.00207.x; PMid:23050698

21. Samir R, Asplund A, Tot T et al. 2012. Oral contraceptive and progestinonly use correlates to tissue tumor marker expression in women with cervical intraepithelial neoplasia. Contraception 85(3):288–293. http://dx.doi.org/10.1016/j.contraception.2011.09.001; PMid:22067748

22. Efird JT, Toland AE, Lea CS, Phillips CJ. 2011. The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinoma. Clin Med Insights Oncol. 27(5):55–75. http://dx.doi.org/10.4137/CMO.S6905; PMid:21499554 PMCid:PMC3076039

23. Veljkovic M, Veljkovic S. 2010. The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl. 63(9–10):657–661. http://dx.doi.org/10.2298/MPNS1010657V; PMid:21446095